Target intelligence / Profile preview

O6-alkylguanine and O4-alkylthymine DNA adducts (O6-AG/O4-AT)

Target
O6-AG/O4-AT
Molecular classification
DNA lesion, DNA modification
01

Overview

O6-alkylguanine and O4-alkylthymine DNA adducts are covalent modifications of DNA bases formed by the action of alkylating agents, such as temozolomide, dacarbazine, and nitrosoureas (Pegg, 2000, NIH). These adducts are highly cytotoxic and mutagenic; O6-methylguanine, for instance, frequently mispairs with thymine during replication, which triggers the mismatch repair (MMR) system and leads to double-strand breaks and apoptosis (Duckett et al., 1996, UNC). O4-alkylthymine adducts, though formed in smaller quantities, are also potent inducers of mutations and are repaired with varying efficiency by alkyltransferases (Pegg, 2000, NIH). The repair of these lesions is primarily mediated by the enzyme O6-methylguanine-DNA methyltransferase (MGMT), which removes the alkyl group in a stoichiometric, suicide reaction (Dolan, 1995, NIH). Because MGMT can confer resistance to alkylating chemotherapies, its expression levels and promoter methylation status are critical biomarkers for predicting treatment efficacy in cancers like glioblastoma (Hegi et al., 2005, NEJM). While these adducts are essential for the therapeutic effect of certain drugs, their mutagenic potential in non-cancerous cells also poses a risk for secondary malignancies and other toxicities (Pegg, 1990, Cancer Research).

Other names
O6-methylguanineO4-methylthymineO6-meGO4-meTAlkylated DNA basesO6-alkyl-GO4-alkyl-TO6-alkylguanine DNA lesions
02

Mechanism of action

Formation of cytotoxic and mutagenic DNA adducts that lead to base mispairing and trigger mismatch repair-mediated cell death.

03

Biological functions

MutagenesisApoptosis inductionDNA damage responseCell cycle arrest
04

Disease associations

CancerGlioblastomaMelanomaLymphomaAstrocytoma
05

Safety considerations

MyelosuppressionSecondary malignancies (e.g., therapy-related leukemia)TeratogenicityInfertilityResistance via MGMT overexpression
06

Interacting drugs

Temozolomide

9 more in the full profile.

07

Biomarkers

MGMT promoter methylation statusMGMT protein expressionO6-methylguanine-DNA methyltransferase activityO6-methylguanine levels in DNA

Beyond the preview

Go deeper on O6-alkylguanine and O4-alkylthymine DNA adducts (O6-AG/O4-AT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on O6-alkylguanine and O4-alkylthymine DNA adducts (O6-AG/O4-AT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call